Trial Profile
An Open Label Randomized, Multi-Centre Exploratory Phase II Study to Evaluate the Efficacy and Safety of the Combination of Panitumumab With FOLFOX 4 Chemotherapy or Panitumumab With FOLFIRI Chemotherapy in Subjects With Wild- Type KRAS Colorectal Cancer and Liver-Only Metastases
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Liver metastases; Rectal cancer
- Focus Therapeutic Use
- Acronyms PLANET
- 01 Feb 2018 Results of pooled data from PRIME (NCT00364013), PEAK (NCT00819780) and PLANET (NCT00885885) assessing impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment with panitumumab, were published in the Journal of Cancer Research and Clinical Oncology.
- 12 Sep 2017 Results of pooled data from two trial (MACRO-2 and PLANET) assessing the impact of tumor location on the efficacy of first line anti-EGFR monoclonal antibody plus chemotherapy in patients with metastatic colorectal cancer, were presented at the 42nd European Society for Medical Oncology Congress.
- 17 Jun 2017 Results published in the European Journal of Cancer